Company: ARTL
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001640334-25-000825
Chunk: 111

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 111
---
ARTELO BIOSCIENCES, INC.

Consolidated Balance Sheets

(Unaudited)

(In thousands, except share data)

   March 31,    December 31,    2025  2024        ASSETS      Current Assets      Cash and cash equivalents $746  $2,338 Prepaid expenses and other current assets  212   219 Deferred offering costs  424   - Total Current Assets  1,382   2,557 Operating lease right-of-use assets  91   99 Intangible asset  2,039   2,039 Other assets  3   3 TOTAL ASSETS $3,515  $4,698          LIABILITIES AND STOCKHOLDERS' EQUITY        Current Liabilities        Accounts payable and accrued liabilities $2,509  $1,676 Due to related parties  23   61 Operating lease liabilities - current portion  36   35 Advances from investors  236   - Total Current Liabilities  2,804   1,772          Operating lease liabilities  59   69 TOTAL LIABILITIES  2,863   1,841          STOCKHOLDERS' EQUITY        Preferred Stock, par value $0.001, 416,667 shares authorized,         0 shares issued and outstanding as of March 31, 2025 and December 31, 2024  -   - Common Stock, par value $0.001, 50,000,000 shares authorized and 3,281,032 shares issued and outstanding as of March 31, 2025, and December 31, 2024  3   3 Additional paid-in capital  53,384   53,192 Accumulated deficit  (52,508)  (50,136)Accumulated other comprehensive loss   (227)  (202)TOTAL STOCKHOLDERS' EQUITY  652   2,857          TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $3,515  $4,698 

 3Table of Contents

ARTELO BIOSCIENCES, INC.

Consolidated Statements of Operations and